BCL2 expression and its correlation with neuroendocrine differentiation in colon carcinomas

Tumori

Volumn 90, Issue 2, 2004, Pages 233-238

  Atasoy, Pinar ^a,c   Bozdoǧn, Önder ^a   Öztürk, Sibel ^b   Ensari, Arzu ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c Kirim Caddesi   (Turkey)

Author keywords

BCL2; Chromogranin A; Colon carcinoma; Neuroendocrine differentiation

Indexed keywords

CHROMOGRANIN A; PROTEIN BCL 2;

ADENOCARCINOMA; ADENOMATOUS POLYP; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CELL PROTECTION; CLINICAL ARTICLE; COLON CARCINOMA; COLON MUCOSA; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE CRYPT; MALE; MUCINOUS CARCINOMA; NEUROENDOCRINE SYSTEM; NEUROSECRETORY CELL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 2942525508     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000213     Document Type: Article

References (31)

1. Jiang SX, Kameya T, Sato Y, Yanase N, Yoshimura H, Kodama T: Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol, 148: 837-846, 1996.
2. Merry DE, Veiss DJ, Hickey WF, Korsmeyer SJ: Bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS. Development, 120: 301-311, 1994.
3. Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D: Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res, 51: 6529-6538, 1991.
4. Ramani P, Lu QL: Expression of bcl-2 gene product in neuroblastoma. J Pathol, 172: 273-278, 1994
5. Van den Oord JJ, Vandeghinste N, Ley MD, Wolf-Peeters CD: Bcl-2 expression in human melanocytes and melanocytic tumours. Am J Pathol, 145: 294-300, 1994.
6. Staren ED, Gould VE, Jansson DS, Hyser M, Goouch GT, Economou SG: Neuroendocrine differentiation in "poorly differentiated" colon carcinomas. Am Surg, 56: 412-419, 1990.
7. Hamada Y, Oishi A, Shoji T, Takada H, Yamamura M, Hioki K, Yamamoto M: Endocrine cells and prognosis in patients with colorectal carcinoma. Cancer, 69: 2641-2646, 1992.
8. Foley EF, Gaffey MJ, Frierson HF: The frequency and clinical significance of neuroendocrine cells with stage III adenocarcinomas of the colon. Arch Pathol Lab Med, 122: 912-914, 1998.
9. De Bruine AP, Wiggers Th, Beek C, Volovics A, Von Meyenfeld M, Arends JW, Bosman FT: Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer, 54: 765-771, 1993.
10. Hermanek P, Frühmorgen P, Guggenmoos-Holzmann I: The malignant potential of colorectal polyps: a new statistical approach. Endoscopy, 15: 16-20, 1983.
11. Sinicrope FA, Hart J, Michelassi F, Lee JJ: Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res, 1: 1103-1110, 1995.
12. Segal NH, Cohen RJ, Haffejee Z, Savage N: BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med, 118: 616-618, 1994.
13. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C: BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene, 9: 3367-3370, 1994.
14. Manne U, Weiss HL, Grizzle WE: Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. Int J Cancer, 89: 423-430, 2000.
15. Kaklamanis L, Savage A, Mortensen N, Tsiotos P, Doussis-Anagnostopoulou I, Biddolph S, Whitehouse R, Harris AL, Gatter KC: Early expression of bcl-2 protein in the adenomacarcinoma sequence of colorectal neoplasia. J Pathol, 179: 10-14, 1996.
16. Krajewska M, Moss SF, Krajewski S, Song Ki, Holt PR, Reed JC: Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res, 56: 2422-2427, 1996.
17. Backus HH, Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM, Peters GJ: Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol, 55: 206-211, 2002.
18. Baretton GB, Diebold J, Christoforis G, Vogt M, Muller C, Dopfer K, Schneiderbanger K, Schmidt M, Lohrs U: Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer, 77: 255-264, 1996.
19. Flohil CC, Janssen PA, Bosmon FT: Expression of BCL-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J Pathol, 178: 393-397, 1996.
20. Kang M, Mitomi H, Sada M: Ki-67, p53, and Bcl-2 expression of serrated adenomas of the colon. Am J Surg Pathol, 21: 417-423, 1997.
21. Krajewski KS, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC: Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol, 145: 1323-1336, 1994.
22. Tateyama H, Li W, Takahashi E, Miura Y, Sugiura H, Eimoto T: Apoptosis index and apoptosis-related antigen expression in serrated adenoma of the colorectum. Am J Surg Pathol, 26: 249-256, 2002.
23. Leahy DT, Mulcahy HE, O'Donoghue DP, Parfrey NA: Bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology, 35: 360-367, 1999.
24. Dursun A, Poyraz A, Suer O, Akyol G: Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol Oncol Res, 7: 24-27, 2001.
25. Bosari S, Moneghini L, Graziani D, Lee AK, Murray JJ, Coggi G, Viale G: Bcl-2 oncoprotein in colorectal hyperplastic potyps polyps, adenomas, and adenocarcinomas. Hum Pathol, 26: 534-540, 1995.
26. Buckolm IK, Nesland JM: Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Wirchows Arch, 436: 224-228, 2000.
27. Saleh HA, Jackson H, Khatib G, Banerjee M: Correlation of bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia. Pathol Oncol Res, 5: 273-279, 1999.
28. Indinnimeo M, Cicchini C, Memeo L, Stazi A, Provenza C, Ricci F, Mingazzini PL: Correlation between chromogranin-A expression and pathological variables in human colon carcinoma. Anticancer Res, 22: 395-398, 2002.
29. Di Sant' Agnese PA: Identification and pathologic significance of neuroendocrine differentiation in human prostate carcinoma. In: Pathology of the prostate, Foster CS, Bostwick DG (Eds), pp 352-363, WB Saunders, Philadelphia, 2000.
30. Park JG, Choe GY, Helman LJ: Chromogranin-A expression in gastric and colon cancer tissues. Int J Cancer, 51: 189-194, 1992.
31. Jansson D, Gould VE, Gooch GT: Immunohistochemical analysis of colon carcinomas applying exocrine and neuroendocrine markers. APMIS, 96: 1129-1139, 1988.